US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Pulse Biosciences, Inc - Common Stock (NQ:PLSE)

47.90 -1.93 (-3.87%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pulse Biosciences, Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Pulse Biosciences’ nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual Meeting
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Cash Jumps in Q2 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Pulse Biosciences Inc (NASDAQ:PLSE) Reports Q2 2025 Earnings: Wider Loss, Clinical Progress in Focus ↗
Pulse Biosciences reported a Q2 2025 net loss of $0.28 per share, slightly wider than estimates, with no revenue. The company advances its nsPFA tech in clinical trials, focusing on atrial fibrillation... 
Via Chartmill
News headline image
Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025
From Pulse Biosciences
Via Business Wire
News headline image
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Earnings Scheduled For August 12, 2025 ↗
 
Via Benzinga
News headline image
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences To Present at the BofA Securities 2025 Health Care Conference
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences’ Nanosecond PFA Technology to be Featured at The American Association for Thoracic Surgery 2025 Annual Meeting
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences’ Nanosecond PFA Technology to be Featured at The Heart Rhythm Society 2025 Annual Meeting
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗
The regular session of the US market on Wednesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Earnings Scheduled For March 27, 2025 ↗
 
Via Benzinga
News headline image
Pulse Biosciences To Present at the 24th Annual Needham Virtual Health Care Conference
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences’ Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting
From Pulse Biosciences, Inc.
Via Business Wire
News headline image
Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium
From Pulse Biosciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >